Vasculitis & polymyalgia rheumatica
Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in antineutrophil cytoplasm antibody (ANCA)-associated vasculitis: predefined 2-year follow-up study
Authors' conclusion
At 24 months, frequencies of relapse did not differ between the groups, and SAEs were less frequent in the reduced-dose group due to the lower event rate in the 6-month induction phase.
Study context
- Population
- New-onset AAV without severe glomerulonephritis or alveolar haemorrhage; rituximab maintenance (1 g/6 months) after remission134 analysed
- Participants
- 140 participants
- Comparison
- Reduced-dose vs high-dose prednisolone, each plus rituximab
Methodological detailspredefined 2-year follow-up
- Predefined 2-year follow-up
Primary result
As reported in the abstract
Relapse · 24 months
P = 0.311
Further findings
Prednisolone discontinuation among patients achieving remission
Median time to withdrawal Reduced-dose 150 days · High-dose 375 days
| Outcome | Reduced-dose | High-dose | P value |
|---|---|---|---|
| Death · 24 months | 2.8% | — not stated in the abstract | P = 0.225 |
— not stated in the abstract
Safety
Serious adverse events · 24 months
P = 0.025
Events Reduced-dose 36 · High-dose 54
Original publication
Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study. Ann Rheum Dis. Published 2 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →